Quinazolines as inhibitors of endothelin converting enzyme

US5658902A · kind A · utility

Assignee

• WARNER-LAMBERT COMPANY LLC · US

Inventors

• Kyunghye Ahn · Ann Arbor, US
• Xue-Min Cheng · Ann Arbor, US
• Annette Marian Doherty · Ann Arbor, US
• Edward Faith Elslager · Ann Arbor, US
• Brian Kornberg · Ann Arbor, US
• Chitase Lee · Ann Arbor, US
• Daniele Leonard · Ann Arbor, US
• Sham Nikam · Ann Arbor, US
• Leslie M. Werbel · Ann Arbor, US

Key dates

• Filing date: Dec 22, 1994
• Grant date: Aug 19, 1997
• Expiry date: Dec 22, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D453/02
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.